VTL - Vital Therapies, Inc.

Vital Therapies, Inc. (VTL) was a biopharmaceutical company that focused on the development of cell-based therapies for the treatment of acute liver failure and other liver diseases. The company's lead product candidate was ELAD (Extracorporeal Liver Assist Device), a liver support system that used human liver cells to treat patients with acute liver failure.

However, in 2019, VTL announced that it had terminated the Phase 3 clinical trial of ELAD after the trial did not meet its primary endpoint. As a result, the company discontinued the development of ELAD and subsequently closed down its operations.

As of today, March 4, 2023, VTL is no longer trading as a public company, and its current financial performance is not available. However, investors should note that investing in biopharmaceutical companies like VTL carries market risks, including the risk of clinical trial failure, regulatory approval delays, competition, and changes in healthcare policies and regulations.

Additionally, the biopharmaceutical industry is subject to significant research and development costs, and the success of a company's products is often uncertain until clinical trials are completed. Investors should carefully consider these risks before investing in VTL or any other biopharmaceutical company and consult with a financial advisor to determine if it is an appropriate investment for their portfolio. They should also review the company's public disclosures and financial statements to gain a better understanding of its financial performance and risks.